BAQSIMI 3 mg pdr appl nasale

7680674650010 CH-67465 H04AA01 07.06.3.

Active substances:

BAQSIMI 3 mg pdr appl nasale
Fiches Amavita / Sun Store / Coop Vitality

Details

Product number
6746501
CPT
-
Packaging group
1
Unit
Stück
Composition
glucagonum 3 mg, betadexum, dodecylphosphocholinum, ad pulverem.

Articles (1)

Baqsimi, Nasenpulver
Nasenpulver
1
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
18/06/2026
Patient information leaflet
Français
18/06/2026
Patient information leaflet
Italien
18/06/2026
Professional SmPC
Allemand
18/06/2026
Professional SmPC
Français
18/06/2026
Professional SmPC
Italien
18/06/2026

Detailed composition

Substance Quantity Type Category
glucagonum
3.0 MG Substance Wirkstoff (Principe actif)
betadexum
- Substance HNIDK
dodecylphosphocholinum
- Substance HNIDK

Reimbursement information

Public price
CHF 61.90
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/10/2022

Authorization holder

Future Health Pharma GmbH

8620 Wetzikon ZH

Authorization information

Swissmedic authorization number
67465
Drug name
Baqsimi, Nasenpulver
Galenic form
NASP
ATC Code
H04AA01
Authorization status
Z
Dispensation category
B
First authorization
11/06/2020
Authorization expiration date
31/12/9999
IT number
07.06.3.
Domain
Human medicine
Field of application
schwere Hypoglykämie bei Erwachsenen, Jugendlichen und Kindern ab 1 Jahr mit Diabetes mellitus

Packaging details

Description (FR)
BAQSIMI 3 mg pdr appl nasale
Description (DE)
BAQSIMI 3 mg Pulv zur nasal Anwendung
Market launch
11/06/2020
Narcotic (BTM)
No
Buy us a coffee Explore the data